Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | PPARG | P37231 | 7/20 | 0.59 |
| ▸ | PPARD | Q03181 | 7/20 | 0.59 |
| ▸ | PPARA | Q07869 | 7/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.59 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | FABP4 | P15090 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414339 | 1.00 | FFAR4 (0.61) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL24882733 | 1.00 | FFAR4 (0.61) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL4405746 | 1.00 | FFAR4 (0.61) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL24882730 | 0.94 | FFAR4 (0.54) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL10032088 | 0.93 | LMNA (0.66) | FFAR4TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL421573 | 0.93 | LMNA (0.66) | FFAR4TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL14666437 | 0.93 | LMNA (0.66) | FFAR4TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL424085 | 0.93 | LMNA (0.66) | FFAR4TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL14666520 | 0.93 | LMNA (0.66) | FFAR4TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL336544 | 0.93 | LMNA (0.66) | FFAR4TSHRALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025123147-A1 | TOLERIZING IMMUNOMODULATORY COMBINATION | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2025-06-19 | — | — | WO | disclosed |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| EP-4398930-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | Integrated Nanotherapeutics Inc. (CA) | 2024-07-17 | — | — | EP | disclosed |
| CN-118215496-A | Immunomodulatory combinations of antigens and drug-lipid conjugates | 集成纳米治疗股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023035068-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2023-03-16 | — | — | WO | disclosed |
| US-20220226480-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-21 | — | — | US | disclosed |
| EP-3941897-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | Integrated Nanotherapeutics Inc. (CA) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020191477-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
| EP-2132283-A1 | TRIESTER-BASED LUBRICANTS AND METHODS OF MAKING SAME | Chevron U.S.A., Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008124294-A1 | TRIESTER-BASED LUBRICANTS AND METHODS OF MAKING SAME | CHEVRON U.S.A. INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | LY96, CD74, TLR9 | FFAR4 976/4885FFAR1 1614/4885GPR84 1449/4885 |
| US-20220226480-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | LPXN, MLX, MGLL | FFAR4 929/4885FFAR1 1039/4885GPR84 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.